These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 1786145)

  • 21. Antibody responses of chimpanzees immunized with synthetic peptides corresponding to full-length V3 hypervariable loops of HIV-1 envelope glycoproteins.
    Neurath AR; Jiang S; Strick N; Kolbe H; Kieny MP; Muchmore E; Girard M
    AIDS Res Hum Retroviruses; 1991 Oct; 7(10):813-23. PubMed ID: 1720628
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mother-to-infant transmission of human immunodeficiency virus type 1: association with prematurity or low anti-gp120.
    Goedert JJ; Mendez H; Drummond JE; Robert-Guroff M; Minkoff HL; Holman S; Stevens R; Rubinstein A; Blattner WA; Willoughby A
    Lancet; 1989 Dec; 2(8676):1351-4. PubMed ID: 2574302
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patterns of immunoglobulin G subclass reactivity to HIV-1 envelope peptides in children born to HIV-1-infected mothers.
    Jansson M; Wahren B; Scarlatti G; Principi N; Lombardi V; Livadiotti S; Elia L; Plebani A; Wigzell H; Rossi P
    AIDS; 1992 Apr; 6(4):365-71. PubMed ID: 1616634
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Maternal Binding and Neutralizing IgG Responses Targeting the C-Terminal Region of the V3 Loop Are Predictive of Reduced Peripartum HIV-1 Transmission Risk.
    Martinez DR; Vandergrift N; Douglas AO; McGuire E; Bainbridge J; Nicely NI; Montefiori DC; Tomaras GD; Fouda GG; Permar SR
    J Virol; 2017 May; 91(9):. PubMed ID: 28202762
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Seroreactivity of analogous antigenic epitopes in glycoprotein 120 expressed in HIV-1 subtypes A, B, C, and D.
    Pestano GA; Hosford KS; Spira AI; Riley J; Xie JM; Sewankambo N; Brown L; Ho DD; Boto WM
    AIDS Res Hum Retroviruses; 1995 May; 11(5):589-96. PubMed ID: 7576915
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
    Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
    Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Simultaneous introduction of distinct HIV-1 subtypes into different risk groups in Russia, Byelorussia and Lithuania.
    Lukashov VV; Cornelissen MT; Goudsmit J; Papuashvilli MN; Rytik PG; Khaitov RM; Karamov EV; de Wolf F
    AIDS; 1995 May; 9(5):435-9. PubMed ID: 7639968
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlation between anti-V3 peptide and neutralizing antibodies in plasma from HIV-1 infected individuals resident in Brazil.
    Bongertz V; Morgado MG; Galvão-Castro B; Wigzell H; Hendry RM
    Mem Inst Oswaldo Cruz; 1994; 89(1):113-4. PubMed ID: 7823807
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evidence for non-V3-specific neutralizing antibodies that interfere with gp120/CD4 binding in human immunodeficiency virus 1-infected humans.
    Kang CY; Nara P; Chamat S; Caralli V; Ryskamp T; Haigwood N; Newman R; Köhler H
    Proc Natl Acad Sci U S A; 1991 Jul; 88(14):6171-5. PubMed ID: 2068099
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neutralizing antibodies and viral characteristics in mother-to-child transmission of HIV-1.
    Scarlatti G; Leitner T; Hodara V; Halapi E; Rossi P; Albert J; Fenyö EM
    AIDS; 1993 Nov; 7 Suppl 2():S45-8. PubMed ID: 8161445
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibodies to V3 loop peptides derived from chimpanzee lentiviruses and the divergent HIV-1ANT-70 isolate in human sera from different geographic regions.
    Peeters M; Nkengasong J; Willems B; Karita E; Delaporte E; Van den Haesevelde M; Piot P; van der Groen G
    AIDS; 1994 Dec; 8(12):1657-61. PubMed ID: 7888113
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Maternofetal transmission of human immunodeficiency virus-1: the role of antibodies to the V3 primary neutralizing domain.
    Rubinstein A; Goldstein H; Calvelli T; Devash Y; Rubinstein R; Soeiro R; Lyman W
    Pediatr Res; 1993 Jan; 33(1 Suppl):S76-8; discussion S78-9. PubMed ID: 8433879
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recognition properties of V3-specific antibodies to V3 loop peptides derived from HIV-1 gp120 presented in multiple conformations.
    Huisman JG; Carotenuto A; Labrijn AF; Papavoine CH; Laman JD; Schellekens MM; Koppelman MH; Hilbers CW
    Biochemistry; 2000 Sep; 39(35):10866-76. PubMed ID: 10978173
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Passive immunization to prevent mother-infant transmission of human immunodeficiency virus: current issues and future directions.
    Mofenson LM; Burns DN
    Pediatr Infect Dis J; 1991 Jun; 10(6):456-62. PubMed ID: 1712936
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity comparison of a multi-antigenic peptide bearing V3 sequences of the human immunodeficiency virus type 1 with TAB9 protein in mice.
    Cruz LJ; Quintana D; Iglesias E; Garcia Y; Huerta V; Garay HE; Duarte C; Reyes O
    J Pept Sci; 2000 May; 6(5):217-24. PubMed ID: 10823490
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Measurement of cerebrospinal fluid antibody to the HIV-1 principal neutralizing determinant (V3 loop).
    Lucey DR; VanCott TC; Loomis LD; Bethke FR; Hendrix CW; Melcher GP; Redfield RR; Birx DL
    J Acquir Immune Defic Syndr (1988); 1993 Sep; 6(9):994-1001. PubMed ID: 7688046
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Methods for analysis of biologically functional antibodies to the HIV-1 gp120 principal neutralizing domain.
    Devash Y; Rusche JR; Nara PL
    Biotechnol Ther; 1991; 2(1-2):49-62. PubMed ID: 1845124
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
    Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
    Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peptides mimicking selected disulfide loops in HIV-1 gp120, other than V3, do not elicit virus-neutralizing antibodies.
    Neurath AR; Strick N; Fields R; Jiang S
    AIDS Res Hum Retroviruses; 1991 Aug; 7(8):657-62. PubMed ID: 1718344
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Geographical distribution of HIV-1 group O viruses in Africa.
    Peeters M; Gueye A; Mboup S; Bibollet-Ruche F; Ekaza E; Mulanga C; Ouedrago R; Gandji R; Mpele P; Dibanga G; Koumare B; Saidou M; Esu-Williams E; Lombart JP; Badombena W; Luo N; Vanden Haesevelde M; Delaporte E
    AIDS; 1997 Mar; 11(4):493-8. PubMed ID: 9084797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.